News for Inhibrx Inc (1RK.BE)

Today's Daily Dose brings you news about temporary suspension of bluebird bio's gene therapy trials in sickle cell disease, Sesen Bio's regulatory catalyst for this year, partial hold on Cortexyme's open-label extension phase of its ongoing phase II/III study of Atuzaginstat for Alzheimer's disease, and expanded FDA approval of Novartis' Entresto.

(RTTNews) - Today's Daily Dose brings you news about temporary suspension of bluebird bio's gene therapy trials in sickle cell disease, Sesen Bio'...

SAN DIEGO, Feb. 1, 2021 /PRNewswire/ --?Inhibrx, Inc. , a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, announced... | February 1, 2021